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CCThe hyperdynamic syndrome is a late consequence of portal hypertension in cirrhosis. The principal hemody-
namic manifestations of the hyperdynamic syndrome are high cardiac output, and increased heart rate and
total blood volume, accompanied by reduced total systemic vascular resistance. Pathophysiology involves a
complex of humoral and neural mechanisms that can determine hemodynamic changes, and lead to
hyperdynamic circulation.
In this review we focus our attention on the manifestations of the hyperdynamic syndrome. Some of these are
well described and directly related to portal hypertension (varices, ascites, hepatic encephalopathy, and
hepatorenal syndrome), while others, such as hepatopulmonary syndrome, portopulmonary hypertension, and
cirrhotic cardiomyopathy, are less known as clinical manifestations related to cirrhosis and, therefore, merit
further investigation.
© 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Patients with advanced chronic liver disease show varying degrees
of portal hypertension (PH) and splanchnic vasodilatation, which
are often associated with a hyperdynamic circulatory state. The
hyperdynamic syndrome (HS) is a consequence of cirrhosis of varying
etiologies [1,2]. This syndrome has been deﬁned by high cardiac output,
increased heart rate and total blood volume, reduced total systemic
vascular resistance, and low, normal or decreased arterial pressure
[1–3]. In this review, we will attempt to describe and explain the
pathophysiological and clinical manifestations related to HS.1.1. Hemodynamic changes contributing to hyperdynamic syndrome
Among all hemodymanic alterations typical of advanced phases of
cirrhosis, vasodilatation is the ﬁrst of vascular changes that ﬁnally lead
to multi-organ involvement. However, the mechanisms of vasodilation
are still not entirely understood [2].al hypertension; HPVG, Hepatic
; HE, Hepatic encephalopathy;
hypertension;HH, Hepatic hy-
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cine. Published by Elsevier B.V. All rig
inical implications of the hypDevelopment of PH due to architectural changes typical of cirrhosis
plays a fundamental role in the genesis of HS. In fact, PH consists of an
increase in portal pressure gradient (HVPG), deﬁned by the difference
between the portal vein and the inferior vena cava pressures [4]. It is
caused by an increased resistance to portal outﬂow and inﬂow, with
an abnormal distribution of the blood volume, which increases mostly
in the splanchnic district. This alteration of blood volume distribution
with underﬁlling of arterial circulation triggers baroreceptor activation
to release vasoconstrictor factors to restore integrity of the circulation
[5]. Usually, the HVPG ranges from 1 to 5 mmHg, becoming clinically
signiﬁcantwhen it reaches 10mmHg [6]. In clinical practice, an increase
in HPVG values of at least 12 mmHg is usually associated with the
presence of esophageal varices [2,6]. Progressing through the stages of
cirrhosis, there is a wide development of a network of collateral vessels,
which bypassing the liver, creates communication between the portal
vein and the systemic circulation. The main collateral network is
the gastro-epiploic system, responsible for the formation of gastro-
esophageal varices, which together with the reduction in circulating
platelets and hypersplenism are the clinical hallmark of PH [5–7].
Splanchnic circulation is responsible for the reduction of vascular
resistance in the portal hypertensive state. The increase in splanch-
nic blood ﬂow is related to: 1.) an increase in vasodilatator factors
(nitric oxide (NO), prostacyclines, carbon monoxide (CO), endo-
cannabinoides); 2.) reduced response to vasoconstrictor factors;
and 3.) mesenteric neoangiogenesis [8–11]. The increase in NO,
maintained in pre-sinusoidal areas, is due to endothelial nitric
oxide synthase activation by pro-inﬂammatory cytokines released
by bacterial translocation and shear stress. Moreover, the splanchnic
vasodilatation is caused by reduced response to vasoconstrictorhts reserved.
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kidney and brain. The reduced response to local vasoconstrictors is
likely related to increased levels of vasodilatator factors (NO, CO),
and functional alterations of smooth muscular and endothelial cells.
At early compensated stages of cirrhosis, hyperdynamic circulation
is not clinically manifest, but becomes more evident during the evolu-
tion of the disease. Any modiﬁcation in peripheral resistance is rapidly
compensated by variations in cardiac output. Though the reduction in
peripheral resistance is slow, compensatory mechanisms play a pivotal
role in maintaining and further worsening the hyperdynamic circula-
tion (Fig. 1) [12–16]. Plasma volume expansion is relevant in these cir-
rhotic patients, even if distribution between the central and peripheral
vascular areas is often not balanced [6,17]. The splanchnic vasodilation
in cirrhosis precedes the increase in cardiac output and heart rate [18].
However, when the splanchnic vasodilatation becomes more pro-
nounced, the hyperdynamic circulation may no longer be sufﬁcient for
correcting hypovolemia [12,17] (Fig. 2). Central arterial blood volume
(heart, lungs, and central arterial tree blood volume) is more often
decreased, while the non-central blood volume (splanchnic) is usually
increased in cirrhotics.
2. Clinical manifestations
The ﬁrst described clinical signs of the HSwere arterial hypotension,
wide pulse pressure, tachycardia, warm extremities and palmarFig. 1.Mechanisms leading to hyperdynamic circulation. Two hypotheses are advanced to expla
duction of circulating vasodilators (intestinal or systemic); vasodilators escaping the degradation
in vasoconstrictors, and an increase in vasodilators. Porto-systemic vessels allow gut-derived hu
into the systemic circulation. The neural dysregulation hypothesis suggests that chemoreceptor
central cardiovascular-regulatory nuclei via afferent nerves. (CBV: central blood volume; HVP
BV: blood volumes; RVR: renal vascular resistance; RBF: renal blood ﬂow; SVR: systemic vas
RAAS: renin–angiotensin–aldosterone system; AVP: arginine vasopressin; ET: endothelin).
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of clinical complications of cirrhosis, while PH and its sequelae are a
cause of admission to the hospital, worsening of clinical conditions, and
death. In fact, esophageal or gastric variceal bleeding, ascites with conse-
quent spontaneous bacterial peritonitis (SBP), hepatic encephalopathy
(HE), and hepato-renal syndrome (HRS) are closely related to PH.
However, the effects of hyperdynamic circulation also involve the
heart (cirrhotic cardiomyopathy [CC]) and the lungs (hepatopulmonary
syndrome [HPS], portopulmonary hypertension [POPH] and hepatic hy-
drothorax [HH]). Clinical manifestations are listed in Table 1.
2.1. Cutaneus and muscular manifestations
Cutaneous and muscular circulations may be increased in patients
with cirrhosis. Palmar erythema, spider nevi and potatory face were
recognized early on as clinical signs of cutaneous hyperperfusion [19].
These manifestations are expressions of artero-venous ﬁstulae, which
result in increased perfusion of the capillary bed.
Contrasting data from the literature show that in cirrhotic patients
muscular perfusion can be increased or normal [20,21]. Recent studies
have reported that brachial and/or femoral artery blood ﬂow investigat-
ed with Doppler techniques is normal, as is capillary skin blood ﬂow
studied by nuclear medicine techniques [22]. Thus, with the available
data, it is not possible to determine the exact distribution of cardiac
output among organs, tissues, and the capillary bed.in themechanism leading to hyperdynamic circulation: The humoral includes an overpro-
in thediseased liver or bypassing the liver through theporto-systemic shunts; a reduction
moral substances, such as glucagon, bile acid and calcitonin gene-related peptide to enter
s and baroreceptors of the mesenteric area are activated by PH, and signals are related to
G: hepatic vein portal gradient; CO: cardiac output ; HR: heart rate; PV: plasma volume;
cular resistance; MAP: mean arterial blood pressure; SNS: sympathetic nervous system;
erdynamic syndrome in cirrhosis, Eur J Intern Med (2014), http://
Fig. 2. Potential vasodilating and vasoconstricting factors involved in the splanchnic hemodynamic changes of cirrhosis. NO: nitric oxide; TNF-a: tumor necrosis factor alpha; PGI2:
prostaglandin I2; ANP: atrial natriuretic peptide; ET-3: endothelin-3; BNP: brain natriuretic peptide; CO: carbon monoxide; ATII: angiotensin II; SNS: sympathetic nervous system;
ET-1: endothelin-1; RAAS: renin–angiotensin–aldosterone system; ADH: vasopressin.
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The immediate clinical manifestations following the increase in
portal pressure are esophageal varices and, eventually, their bleeding.
Among compensated cirrhotic patients with elevated HVPG, gastroin-
testinal tract endoscopy reveals that 40% already have esophageal
varices. Among those without varices, these will appear at a rate of
6% per year. Esophageal varices are present in approximately 30–40%
patients with compensated cirrhosis at ﬁrst observation, and in up to
60% of those with decompensation. Clinically, physical examination
provides direct information on the presence of PH. In fact, the presence
of splenomegaly, spider nevi, and abdominal wall collateral circulation
are indicative of PH, though the sensitivity of physical signs in compen-
sated cirrhotic patients is quite low. In a recent study, spider nevi were
found to be independent predictors of esophageal varices [23].Table 1
Clinical manifestations of the hyperdynamic syndrome.
Organs Manifestations
Muscle and skin Palmar erythema; spider nevi (partially related)
Hepato-splanchnic Esophageal varices and bleeding;
ascites and spontaneous bacterial peritonitis
Kidney Hepatorenal syndrome
Brain Edema/Hepatic encephalopathy
Lungs Hepatopulmonary syndrome, portopulmonary
hypertension, hepatic hydrothorax
Heart Cirrhotic cardiomyopathy
Please cite this article as: Licata A, et al, Clinical implications of the hyp
dx.doi.org/10.1016/j.ejim.2014.09.004The gold-standard technique for assessing portal hypertension is the
measurement of HVPG. Measurement of HVPG by catheterization of the
right jugular vein (or the femoral or antecubital vein) is an invasive
technique, which limits its use. Recently, spleen stiffness has been
proposed as a new non-invasive parameter for predicting clinically
signiﬁcant portal hypertension and varices. Data on use of magnetic
resonance, transient real-time elastography and ARFI appear more
promising [23]. However, upper gastrointestinal tract endoscopy is
still the gold standard for identifying esophageal and gastric varices,
and is essential in the therapeutic management of variceal bleeding,
through sclerotherapy and elastic band ligation [24].
Screening patients with endoscopy to prevent variceal rupture and
bleeding is mandatory when a diagnosis of cirrhosis has been deter-
mined. The size of varices is semi-quantitatively graded as small, medi-
um or large. Treatment recommendations in patients without varices
includes endoscopy, to be repeated every 2–3 years because the
incidence of esophageal varices is 5–10%/year in this population [25].
In patients with small varices, an annual increase of 10–15% in size is
observed. In these patients, endoscopy should be repeated every
1–2 years. Patients with small varices with red wale marks or Child
C class have an increased risk of bleeding, and should be treated with
nonselective beta-blockers. Moreover, in patients with medium or
large varices, nonselective beta-blockers or band ligation is recom-
mended for prevention of the ﬁrst bleeding. The choice of treatment
should be based on local resources, expertise and contraindications [25,
26]. However, regarding the use of beta blockers, a recent retrospective
study by Mandorfer et al. suggests that they are responsible for an in-
creased hospitalization of hemodynamically compromised patients [27].erdynamic syndrome in cirrhosis, Eur J Intern Med (2014), http://
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emergency in clinical practice. Bleeding occurs in approximately
one-third of cirrhotic patients with varices. The precipitating cause
remains still uncertain, with several factors implicated, such as bacterial
infection, alcohol consumption, and increased intra-abdominal
pressure. Mortality rates related to variceal bleeding are not signiﬁcant
in cirrhotic Child–Pugh Class A or B patients, while it is over 30% in
Child–Pugh Class C [25]. There is a higher likelihood of mortality in
those patients with active bleeding during endoscopy, in those with
advanced cirrhosis (Child–Pugh Class C or a Model for End-Stage Liver
Disease (MELD) score of N20), extra-hepatic organ failure, and high
HVPG (N20 mmHg) [28].
Clinical management of hemorrhage requires airway maintenance
and stabilization of hemodynamic conditions with IV vasoactive drugs
(e.g., somatostatin), with further control of the variceal bleeding with
available endoscopic techniques. According to the latest Baveno V
guidelines, patients who do not respond to these measures are referred
for TIPS as rescue treatment. Re-bleeding rates range from 30% to 40% at
6 weeks, with the mortality rate for rebleeding increased by up to 30%.
At present, a combination of beta-blockers and band ligation is the
preferred therapy for prevention of re-bleeding [25].
2.3. Ascites and spontaneous bacterial peritonitis
The HS plays a major role in the pathogenesis of sodium retention
and ascites in cirrhotic patients [4]. Ascites is themost common compli-
cation of cirrhosis, and about 60% of patients with compensated liver
disease develop ascites during the clinical course of the disease [26].
Mortality is approximately 40% at 1 year, and 50% at 2 years [26–31].
The most reliable predictors of poor prognosis include hyponatremia,
low arterial pressure, increased serum creatinine, and low urine sodium
[31]. Ascites usually occurs after development of PH, and is related to an
incapacity to excrete an adequate amount of sodium into the urine,
leading to a positive sodium balance.
The ﬁrst evaluation of a patient with ascites should include anamne-
sis, physical examination, abdominal ultrasound, liver and renal func-
tion tests, serum and urine electrolytes, and analysis of the ascitic
ﬂuid. A diagnostic paracentesis is needed to exclude heart failure,
pancreatic disease, malignancy, tuberculosis, or SBP. Ascites due to
cirrhotic portal hypertension can be differentiated from ascites due to
other causes by the serum–ascites albumin gradient: if the gradient is
greater than or equal to 1.1 g/dl (or 11 g/L), ascites is due to portal
hypertension, with an accuracy of 97%. Total ascitic ﬂuid protein
concentration should be measured to assess the risk of SBP because
patients with a protein concentration of b15 g/L have a increased risk
of SBP [31].
The current optimal management for mild ascites is a low salt and
water diet. Dietary salt intake should be limited to 80–120 mmol of
sodium a day. Daily monitoring of body weight and urine output is
essential. In patients with moderate ascites, the need for diuretics such
as spironolactone (from 100 mg/day to a maximum of 400 mg/day)
is the ﬁrst step, followed by the introduction of furosemide (from
40 mg/day to 160 mg/day). In these cases, clinical responsiveness will
be measured empirically by a reduction of body weight of less than
2 kg/week. In fact, the correctweight loss duringdiuretic therapy should
vary from 0.5 kg/day to 1 kg/day in patients without or with edema,
respectively. However, the goal of long-term treatment is to avoid
renal impairment, hyponatremia, or severe hyperkalemia and their
clinical manifestations such as hepatic encephalopathy or muscle
cramps.
Large volume paracentesis and albumin infusion is the treatment of
choice for patients with ascites resistant to diuretic treatment [32,33].
Paracentesis is an invasive, though safe procedure, with an extremely
low risk of local complications such as hemorrhage or bowel perfora-
tion. Moreover, in patients with refractory ascites, the insertion of
a transjugular intrahepatic portosystemic shunt (TIPS) should bePlease cite this article as: Licata A, et al, Clinical implications of the hyp
dx.doi.org/10.1016/j.ejim.2014.09.004considered. TIPS placement is not recommended in patients with severe
liver failure and/or cardiopulmonary disease [31].
In the management of ascites it is important to recognize such
ascites-related complications as SBP or HRS. Concerning SBP, bacterial
infection in patients with cirrhosis and ascites is common [30,31,34].
The prevalence of SBP is 1.5–3.5% in outpatients, and about 10% in hos-
pitalized patients [31,35]. Themortality is approximately 20%with early
diagnosis and treatment. The clinical presentation is heterogeneous,
ranging fromasymptomatic patients to thosewith abdominal pain, nau-
sea and vomiting, diarrhea, HE, renal failure, and hepatic insufﬁciency.
A diagnostic paracentesis with a neutrophil count of N250/mm/c
should be obtained to exclude SBP [31]. Ascites ﬂuid culture is negative
in about 40% of cases, but in the remaining cases the most common
pathogens include Gram-negative bacteria (Escherichia coli) and
Gram-positive cocci (mainly streptococcus species and enterococci)
[31,36]. This is important in determining antibiotic therapy, which
usually employs cephalosporins, such as cephotaxime. A second
paracentesis after 48 hours of the start of antibiotic therapy can help
to guide therapy. Patients who recover from an episode of SBP have a
high risk of developing recurrent SBP. The use of prophylactic antibiotics
(norﬂoxacine or ciproﬂoxacine or co-trimoxazole) reduces the likeli-
hood of recurrence [31]. However, patients who recover from SBP
have a poor prognosis, with short-term survival, and should be consid-
ered for liver transplantation.
2.4. Hepato-renal syndrome
The renal circulation is indirectly affected by the consequences of the
hyperdynamic state. The kidney, in response to the relative hypovole-
mia, retains sodium and water. Rather than a decrease in intravascular
volume, the relative hypovolemia is the result of an increase of the
vascular compartment caused by vasodilatation, leading to a reduction
in central blood volume, and activation of vasoconstrictive and volume
retaining neuro-humoral mechanisms that perpetuate the sodium- and
water-retention [4,37].
The HRS is a type of pre-renal failure resulting from an intense
vasoconstriction of the renal circulation, and occurs in patients with
advanced cirrhosis. Exclusion of other causes of renal failure is essential
in arriving at a diagnosis of HRS. There are two clinical types of HRS.
Type 1 HRS is an acute and rapidly progressive form of renal failure,
with a rise in serum creatinine of N2.5 mg/dl, and an expected survival
of only two weeks if the patient is not treated or transplanted [31,38]. It
is common in severe alcoholic hepatitis, in patients with end-stage
cirrhosis with SBP, though in some patients it can occur in the absence
of any identiﬁable triggering event. In type 2 HRS, renal function is
usually less compromised (serum creatinine 1.5–2.5 mg/dl) than in
HRS type 1. The causes of HRS type 2 are usually refractory ascites and
a moderate degree of functional renal failure. The management of HRS
includes the monitoring of diuresis, ﬂuid balance, and arterial pressure.
Treatment options include discontinuing diuretic therapy, screening for
sepsis, eventual antibiotic treatment and ﬁnally TIPS placement [28,31].
The vasopressin-analogue terlipressin, together with the adminis-
tration of albumin, is the ﬁrst-line treatment for type 1 and 2 HRS,
even if there are few data on the role of such drugs and/or vasoconstric-
tors in type 2HRS [31,38–41]. Treatment response usually occurswithin
the ﬁrst 7–10 days, and is associated with an increase in arterial
pressure and urine volume [31,42]. Terlipressin is contraindicated in
patients with ischemic cardiovascular diseases. Monitoring for develop-
ment of cardiac arrhythmias, signs of digital or splanchnic ischemia, and
ﬂuid overload ismandatory. Other vasoconstrictors that have been used
are alpha-adrenergic agonists, particularly noradrenalin, but, again few
data are available [43].
TIPS represents a real treatment option, improving renal function in
type 1 and 2 HRS, but its applicability is limited because of the severe
liver failure. In fact, data from literature are few and survival may not
be greatly improved in patients with poor liver function (advancederdynamic syndrome in cirrhosis, Eur J Intern Med (2014), http://
5A. Licata et al. / European Journal of Internal Medicine xxx (2014) xxx–xxxChild-Pugh score) [31]. However, regarding to this, some authors [44],
reported the effects of TIPS in patients with type 2 HRS and Child-
Pugh score of 10–12, awaiting transplantation. All patients improved
with respect to ascites and renal function thus, they conclude that
TIPS is indicated in selected patients with HRS and/or in candidates for
OLT.
HRS has a poor prognosis, even when vasoactive drug therapies are
used. The impact of vasoactive drugs is poor, although their true
effectiveness consists in prolonging short-term survival as a bridge to
transplantation [45,46].
2.5. Hepatic encephalopathy
HE is a serious neuropsychiatric complication of both acute and
chronic liver failure, with the potential to affect health-related quality
of life. The relation between the systemic vasodilatation occurring
during chronic diseases and the cerebral circulation is probably the
most difﬁcult to delineate. Decreases, as well as increases, in cerebral
blood ﬂow have been reported, while an increase has been associated
mainly with acute liver failure [47]. Studies on cerebral blood ﬂow in
cirrhosis have found that cerebral blood ﬂow is normal in patients
without HE, low or normal in those with subclinical encephalopathy,
and markedly reduced in those with encephalopathy [48]. Dillon et al.
measured themiddle cerebral artery velocitywith transcranial Doppler,
an indirect estimate of cerebral blood ﬂow, in 37 non-encephalopathic
cirrhotic patients with varying degrees of liver dysfunction [49].
The middle cerebral artery velocity was normal in Child A patients,
and signiﬁcantly low in Child B and C patients. Guevara et al. found
that in decompensated cirrhotic patients the cerebral vasoconstriction
is likely related to the arterial hypotension and the hyperactivity of
vasoconstrictor systems [50]. In a study by Lagy et al., cirrhotics were
found to have an altered sympathetic regulation of the cerebral circula-
tion, with inadequate microvessel resistance response, despite an
adequate baroreceptor function [51]. However, though increasing
systemic perfusion pressure is of beneﬁt to the renal circulation, it
could be detrimental to the brain. In fact, in acute liver failure, rises in
cerebral blood ﬂow lead to the development of brain edema [52].
Recently attention has been focused on the role of pro-
inﬂammatory mechanisms that can act synergistically with ammo-
nia toxicity, and result in the cerebral complications of acute and
chronic liver failure [53].
HE is a complex and usually reversible syndrome, frequently
observed in patients with advanced cirrhosis. The West-Haven criteria
have been widely used to subjectively classify these patients according
to the degree of depressed level of consciousness, personality changes,
and neuropsychiatric abnormalities [54]. Because of the lack of typical
features, clinical diagnosis requires a detailed neurological examination
in order to exclude other causes of altered mental status. Clinical man-
agement includes discontinuation of sedative agents or, if necessary,
use of short-acting benzodiazepines or propofol, as these can decrease
intracranial pressure [55]. Symptomatic treatment of encephalopathy
includes bowel decontamination with neomycin or rifaximin, and in-
duction of diarrhea by administration of lactulose, thus reducing ammo-
nia absorption, and treatment with branched-chain amino acids to
improve peripheral ammonia metabolism, though large, randomized
clinical trials have failed to show clinical improvement [56,57].
2.6. Pulmonary complications
2.6.1. Hepatopulmonary syndrome
The hyperdynamic circulation also affects the lungs and pulmo-
nary circulation. Pulmonary involvement in cirrhosis includes two
nosographic entities: HPS and POPH. The ﬁrst occurs in 5–32% of
cirrhotic patients. HPS is deﬁned as the presence of liver disease and/or
PH and intrapulmonary vascular dilatation, resulting in an abnormal
age-corrected alveolar–arterial oxygen gradient (partial pressurePlease cite this article as: Licata A, et al, Clinical implications of the hyp
dx.doi.org/10.1016/j.ejim.2014.09.004of oxygen [PaO2] of b80 mmHg, and an AaPO2 of N15 mmHg, or
N20 mmHg in patients N64 years of age) [58]. A taxonomy of the sever-
ity of theHPS based on alterations in oxygenation is essential because se-
verity inﬂuences survival and is useful in determining the timing and the
risks of orthotopic liver transplantation (OLT) [59,60]. The pulmonary
gas exchange abnormalities of HPS are characterized by hyperventila-
tion and arterial deoxygenation that can be mild (PaO2 b80 mmHg),
moderate (PaO2 b70 mmHg), or severe (PaO2 b60 mmHg) [58]. In
some cases there are no speciﬁc signs and symptoms of the HPS on
physical examination. However, the presence of spider nevi, digital
clubbing, cyanosis and severe hypoxemia (PaO2 b60 mmHg) strong-
ly suggests a diagnosis of this condition. Orthodeoxia and platypnea
seem to be further associated with ventilation-perfusion mismatch
[61,59]. A chest radiograph is not adequate. Contrast-enhanced
echocardiography is the most sensitive diagnostic tool, and com-
monly used in screening cirrhotic patients to detect intrapulmonary
vascular dilatation [62]. No clearly effective medical therapy for HPS
is available, though a number of experimental drugs have been stud-
ied. Currently, OLT is the only effective treatment for patients with
these conditions, and complete resolution of gas exchange abnor-
malities is reported in more than 80% of cases [63]. Clinical practice
indicates that independent of theMELD score, patients with cirrhosis
diagnosed as suffering fromHPSwith a PaO2 b60mmHg are urgently
listed for transplantation [64].
2.6.2. Portopulmonary hypertension
POPH is one of several pulmonary diseases that can affect patients
with liver disease. The prevalence is 8-10 % in patients with cirrhosis.
When pulmonary hypertension occurs in the setting of PH, POPH
develops [65,66]. POPH is deﬁned as an elevated mean pulmonary
artery pressure (MPAP) at the time of right heart catheterization
(MPAP N 25 mmHg, N30 mmHg with exercise), with increased
pulmonary vascular resistance (N240 dines s/cm3), and a pulmonary
occlusion (wedge) pressure ≤15 mm Hg. POPH is classiﬁed as mild
(MPAP b35 mmHg), moderate (MPAP = 35 to b45 mm Hg), or severe
(MPAP ≥45 mm Hg) [64]. Mild POPH is common in cirrhosis, though
usually negligible. Moderate and severe POPH are less common, and
are associated with a higher mortality rate than that predicted by the
MELD score. Pellicelli et al., found that patients with POPH had signiﬁ-
cantly higher levels of endothelin 1 and IL- 6, suggesting a role of
these mediators as targets in the management of POPH [67]. Physical
manifestations can be absent or non-speciﬁc, and dyspnea can be pres-
ent. Echocardiography is required as screening for patients undergoing
OLT evaluations, and right heart catheterization is required to conﬁrm
the diagnosis. The management of POPH includes different classes of
drugs, such as prostacyclin analogues, endothelin receptor antagonists,
and PDE5 inhibitors. Recent data show that sildenaﬁl has the advantage
of being an oral compound with pulmonary vaso-selective action, but
no hepatotoxicity [68,69]. OLT is a potentially curative therapeutic
option for POPH patients. The mortality rate after OLT is 50% if the
MPAP is N35 mm Hg, and 100% if the MPAP is N50 mm Hg [70]. In
fact, efﬁcient pharmacologic control of POPH before transplantation is
associated with post-transplant survival that is similar to that of
patients transplanted for other indications [70,71].
2.6.3. Hepatic hydrothorax
HH is a complication of PH, characterized by a transudative pleural
effusion in the absence of cardiac or pulmonary disease. The estimated
prevalence is 5–10% in cirrhotic patients, predominantly right in 70%
of cirrhotics, left in 18% and bilateral in 12%. Data indicates that only
6.5% of these patients require thoracentesis [72]. The most common
mechanism leading to the passage of ascitic ﬂuid from the peritoneal
to the pleural cavity is the presence of diaphragmatic defects and a
portal hypertensive state [73].
Clinical manifestations include dyspnea, cough, chest discomfort,
hypoxia and, in the most severe cases, respiratory distress. Ascites iserdynamic syndrome in cirrhosis, Eur J Intern Med (2014), http://
6 A. Licata et al. / European Journal of Internal Medicine xxx (2014) xxx–xxxdetected in 80% of these patients. Chest X ray is required to showpleural
effusion. Thoracentesis is indicated to identify other causes of effusion,
ﬂuid infection, and to ameliorate dyspnea. Management includes
diuretics and, occasionally, percutaneus drainage.
As for ascites, a complication ofHH is spontaneous bacterial pleuritis.
A PMN count of N500 cells/mm3 is diagnostic for infection in pleural
effusion, though spontaneous bacterial pleuritis with PMN between
250 and 500 cells/mm3 is documented by positive pleural ﬂuid culture
[74]. In these cases, themortality rate is 20%. Treatment includes antibi-
otic and albumin infusion. In cases of refractory HH, TIPS placement can
be recommended. Thoracoscopy with pleurodesis is a potential treat-
ment alternative for patients with refractory HH who are not eligible
for, or have failed, TIPS placement [75,76].
2.7. Cirrhotic cardiomyopathy
CC is deﬁned as chronic cardiac dysfunction in patients with chronic
liver disease, and is characterized by impaired contractile function in
response to stress, altered diastolic function, and electrophysiological ab-
normalities, in the absence of known cardiovascular disease. This condi-
tion is independent of the etiology of cirrhosis and has been linked to
an impairment of myocardial structure and function [77]. However, sev-
eral studies have reported a wide spectrum of cardiovascular changes in
cirrhotic patients, ranging from the sub-clinical stage of compensated
liver disease to the typical hyperkinetic state of HS in decompensated dis-
ease [78,79]. The prevalence of CC is unknown, because diagnosis is difﬁ-
cult, and cardiac function at rest is usually normal.
Patients with CC remain asymptomatic for a long time because the
arterial vasodilation due to reduced vascular peripheral resistances
leads to a reduction in the after-load, which covers the severe cardiac
dysfunction. Heart failure becomes evident when during certain proce-
dures, such as large volume paracentesis, TIPS placement, and liver
transplantation, there is an acute increase in the cardiac pre-load
following the rise of effective blood volume. A correct diagnosis
becomes evident during the ascitic phase of the cirrhosis, when the
cardiac output is increased.
Echocardiography assessments of systolic and diastolic function,
ECG, or magnetic resonance cardiac imaging are the best available
methods for screening cirrhotic patients at risk of developing CC. Clini-
cal suspicion of CC can be conﬁrmed by pharmacologic (dobutamine
stress echocardiography) or physical stress test (physical exercise)
[80,81]. The impaired systolic response to stress is the trigger of devel-
opment of pulmonary edema and congestive heart failure following
procedures that suddenly increase bloodﬂow to the heart. At-rest cardi-
ac pressures are normal in cirrhosis, so that chamber size modiﬁcations
are modest, as demonstrated by magnetic resonance, likely due to
diastolic dysfunction. A marker of initial cardiac damage has been
indentiﬁed and proven in analysis of NT pro- brain natriuretic peptide
(BNP), a pro hormone of the BNP, commonly used to screen patients
with cardiac dyspnea. NT pro BNP is a sensitive marker of myocardial
injury, and has been found at high levels in both compensated and
decompensated cirrhosis [82]. In fact, it has been recently correlated
with the severity of cirrhosis (Child-Pugh class, HVPG and serum albu-
min), degree of cardiac dysfunction (plasma volume, heart rate and
QT interval) and myocardiac hypertrophy. Diastolic dysfunction is
characterized by an abnormal pattern of transmitral ﬂow and increased
atrial input to the late ventricular ﬁlling. A number of studies have
reported electrophysiological abnormalities as common ﬁndings of car-
diac dysfunction in liver cirrhosis. Electrocardiographic abnormalities
are an early manifestation of cardiac changes in patients with liver
disease: a prolongation of the QT interval, which is the hallmark of the
ECG alterations could be related to severity of liver disease [83,84].
Worsening of cardiac function after OLT, however, is brief and
resolves within about 6 months, when the hyperdynamic circulation
disappears. A normalization of cardiac function and amelioration ofPlease cite this article as: Licata A, et al, Clinical implications of the hyp
dx.doi.org/10.1016/j.ejim.2014.09.004electrophysiological abnormalities are usually observed in these pa-
tients [78,85,86]. In conclusion, clinical understanding of CC in end-
stage liver disease is the best way to avoid life-threatening conse-
quences in patients undergoing special procedures (TIPS or OLT).
3. Conclusions
The HS is a complex of hemodynamic alterations involving patients
with cirrhosis and PH. The pathophysiological mechanisms that
characterize the HS are complex and only partially known.
Multi-organ involvement is crucial, and is characterized by a set of
more or less explored complications of cirrhosis. Clinical manifestations
of PH such as ascites, esophageal varices, and HRS have been described
in numerous studies, while the HPS and CC remain among the least
explored and understood manifestations of HS. Pathophysiological and
hemodynamic studies on both experimental and human models
are needed to better understand the mechanisms involved in these
conditions, and to identify new therapeutic strategies.
Learning points
• In clinical practice, portal hypertension has been deﬁned as an
increase in the hepatic venous pressure gradient (HPVG), and PPG
values of at least 12 mmHg are usually associated with the presence
of esophageal varices.
• Arteriolar vasodilatation, low systemic vascular resistance, expanded
blood volume, and raised sympathetic nervous activity contribute
to increased cardiac output, and to conﬁguring the hemodynamic
changes typical of hyperdynamic circulation.
• Esophageal varices are present in 30–40% of compensated cirrhotic
patients, and in up to 60% of decompensated cirrhotics. Mortality
rates related to variceal bleeding are 30% in Child–Pugh Class C
patients. Upper endoscopy is mandatory in all patients with cirrhosis
at diagnosis.
• The HPS occurs in 5–32% of cirrhotic patients. Typical pattern is gas
exchange abnormalities (PaO2 b80 mmHg; AaPO2 N15 mmHg,
or N20 mmHg in patients N64 years of age), and intrapulmonary
vascular dilation. Patients with a PaO2 b60 mmHg are urgently listed
for liver transplantation.
• Cirrhotic cardiomyopathy is deﬁned as chronic cardiac dysfunction
characterized by impaired contractile function in response to stress,
altered diastolic function, and electrophysiological abnormalities, in
the absence of known cardiovascular disease. Cardiac function usually
improves signiﬁcantly within 6 months after liver transplantation.
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